Zelnick Kaufman Beth 4
4 · CorMedix Inc. · Filed Feb 6, 2026
Research Summary
AI-generated summary of this filing
CorMedix (CRMD) CLO Beth Zelnick Kaufman Receives Award
What Happened
Beth Zelnick Kaufman, Chief Legal Officer of CorMedix, received an award of 36,006 shares (recorded as performance stock units) on February 4, 2026. The reported acquisition price is $0.00 (i.e., an awarded grant rather than a purchase), so the immediate cash value reported is $0. This is an equity compensation grant (transaction code A), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-02-04; Form 4 filed: 2026-02-06 (Accession 0001213900-26-013408).
- Shares/units awarded: 36,006; reported acquisition price: $0.00.
- Shares owned after transaction: Not reported in the information provided.
- Footnote: The award reflects achievement of PSUs for the first of three performance periods for PSUs granted 01/02/2025; these PSUs remain subject to vesting based on time-based conditions.
- Filing timeliness: Filed two days after the transaction date, which appears timely for a Form 4.
Context
Performance stock units (PSUs) are compensation tied to company performance and typically only convert into actual shares if performance and vesting conditions are met; they are not the same as an immediate market purchase. Awards like this are common as part of executive compensation and should be viewed as compensation-related grants rather than a direct personal cash investment or sale.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-04+36,006→ 269,108 total
Footnotes (1)
- [F1]Represents the achievement of performance stock units ("PSUs") upon the determination of the Compensation Committee of the Issuer that the performance conditions specific to the first of three performance periods were met with respect to the PSUs granted to the Reporting Person on January 2, 2025. The PSUs are subject to vesting upon satisfaction of time-based vesting conditions by the Reporting Person.